Novartis Zometa Picks Up 17% Of Company’s Bisphosphonate Business
Executive Summary
Novartis Zometa sales comprise 17% of the company's bisphosphonate business, Oncology President David Epstein said Feb. 7 in reviewing the company's efforts to switch patients from the company's older bisphosphonate oncologic Aredia
You may also be interested in...
Zometa Dosing Study Will Look At Patients With Compromised Renal Function
Novartis' Zometa Phase IV commitments include a study to determine an appropriate dose for patients with severely compromised renal function, following approval of the drug to treat bone metastases
Zometa Dosing Study Will Look At Patients With Compromised Renal Function
Novartis' Zometa Phase IV commitments include a study to determine an appropriate dose for patients with severely compromised renal function, following approval of the drug to treat bone metastases
Novartis Zometa Data Supports Bone Metastases Use Across Tumor Types
Novartis' Zometa data can be used to support a bone metastases indication across tumor types, FDA's Oncologic Drugs Advisory Committee agreed during a Jan. 31 meeting